Cargando…
Cost-Minimisation Analysis of Erythropoiesis-Stimulating Agents in the Treatment of Anaemia in Dialysed Patients: A Pilot Study
OBJECTIVE: This study aimed to assess the cost impact of administering erythropoiesis-stimulating agents once every 4 weeks instead of one to three times a week to treat anaemia in patients undergoing dialysis. METHODS: This was a monocentric retrospective study involving 27 patients who underwent h...
Autores principales: | Darsonval, Astrid, Besson, Virginie, Cavalin, Claire |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5691838/ https://www.ncbi.nlm.nih.gov/pubmed/29441494 http://dx.doi.org/10.1007/s41669-017-0016-5 |
Ejemplares similares
-
Ferric pyrophosphate citrate administered via dialysate reduces erythropoiesis-stimulating agent use and maintains hemoglobin in hemodialysis patients
por: Gupta, Ajay, et al.
Publicado: (2015) -
Combination treatment with an erythropoiesis-stimulating agent and intravenous iron alleviates anaemia in patients with hereditary haemorrhagic telangiectasia
por: Cherif, Honar, et al.
Publicado: (2014) -
Budget impact analysis on erythropoiesis–stimulating agents use for the management of chemotherapy-induced anaemia in Greece
por: Nikolaidi, Eleftheria, et al.
Publicado: (2013) -
Non-erythropoiesis-stimulating agent, non-iron therapies for the management of anaemia: protocol for a scoping review
por: Devlin, Paula, et al.
Publicado: (2022) -
Novel erythropoiesis stimulating protein (NESP) for the treatment of anaemia of chronic disease associated with cancer
por: Smith, R E, et al.
Publicado: (2001)